Olema Oncology Announces New CTA and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement December 4, 2024
Positive Topline Results from Ph 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Announced December 4, 2024
FDA Approves IMKELDI (imatinib) Oral Solution for the Treatment of Certain Forms of Leukemia and Other Cancers December 4, 2024
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer December 4, 2024
Patient Enrollment Expanded for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM as UVA Cancer Center Doses First Patient December 4, 2024
FAILED TRIAL: Ph 3 SKYSCRAPER-01 study of tiragolumab + Tecentriq in patients with PD-L1-high 1L mNSCLC did not reach the primary endpoint of OS December 4, 2024
Kisqali receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence December 4, 2024
Successful Completion of $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline December 4, 2024
Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio December 4, 2024
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies December 4, 2024
Positive Initial Clinical Data Announced in Ph 1 Clinical Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML December 4, 2024
New Data from the OLYMPUS Trial Show mDOR of Four Years in Patients Who Achieved a Complete Response with JELMYTO December 4, 2024
Positive Final Results from Randomized Ph 2 Study of CM24 in 2L Pancreatic Cancer Reported December 4, 2024
FDA Clears IND Application for Ph 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic CRC December 4, 2024
